Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 DiabetesRalph A. DeFronzo, Steven C. Griffen, Marcus Hompesch et al.|Diabetes Care|2013Cited by 289
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2Sreeneeranj Kasichayanula, David W. Boulton, Xiaoni Liu et al.|Clinical Pharmacokinetics|2013Cited by 277
Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human SubjectsChristopher S. Wilcox, Steven C. Griffen, Wen Shen et al.|Journal of the American Heart Association|2018Cited by 137
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjectsSreeneeranj Kasichayanula, David W. Boulton, Xuejun Liu et al.|Diabetes Obesity and Metabolism|2010Cited by 90
Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozinSreeneeranj Kasichayanula, David W. Boulton, Xuejun Liu et al.|Diabetes Obesity and Metabolism|2012Cited by 67